Stock of the Day

Today's Trend

Aethlon Medical, Inc. (NASDAQ: AEMD) shares have decreased in the latest session after an initial surge driven by the company’s proposed merger with North Immunology. Investors are weighing the potential value of North Immunology’s drug pipeline against substantial dilution, execution risks and new shareholder-law-firm investigations.

• Aethlon agreed to an all-stock merger with North Immunology to advance NOR-101, a half-life-extended IL-13 x IL-18 bispecific antibody being developed for atopic dermatitis. The Phase 1a study is expected to begin in the first quarter of 2027, with additional clinical data anticipated through 2028. Aethlon Medical and North Immunology merger announcement
• North Immunology’s oversubscribed private placement is expected to raise $180 million and fund the combined company into the second half of 2028. The financing improves the program’s ability to reach upcoming clinical milestones and helped drive significant investor interest in AEMD. North Immunology financing and Nasdaq listing
• The stock’s sharp merger-related rally has been followed by a pullback, indicating heightened volatility and possible profit-taking as investors assess the transaction’s terms, valuation and the development risk surrounding NOR-101. Aethlon stock pulls back
• Upon closing, existing Aethlon shareholders are expected to own approximately 4.75% of the combined company. That sharply limits their ownership of the prospective drug business and highlights significant dilution from the transaction and financing. Halper Sadeh Aethlon investigation
• Several investor-rights firms, including Monteverde & Associates and Brodsky & Smith, announced investigations into the merger. The firms are examining whether Aethlon’s board obtained adequate value and properly protected shareholders; these are allegations and investigations, not findings of misconduct, but they add legal and transaction uncertainty. Monteverde Aethlon shareholder investigation